翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03692 翰森制药

已收盘 06-02 16:08:46

31.020

-0.120

-0.39%

最高31.600	最低30.740	成交量873.56万
今开31.240	昨收31.140	日振幅2.76%
总市值1,881亿	流通市值1,881亿	总股本60.64亿
成交额2.71亿	换手率0.14%	流通股本60.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"翰森制药","latestPrice":31.02,"timestamp":1780387726007,"preClose":31.14,"halted":0,"volume":8735551,"delay":0,"changeRate":-0.0038535645472061977,"floatShares":6064000000,"shares":6064000000,"eps":1.077958852574653,"marketStatus":"已收盘","change":-0.12,"latestTime":"06-02 16:08:46","open":31.24,"high":31.6,"low":30.74,"amount":271260657,"amplitude":0.027617,"askPrice":31.02,"askSize":4000,"bidPrice":31,"bidSize":76000,"shortable":3,"etf":0,"ttmEps":1.077958852574653,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780450200000},"marketStatusCode":5,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":31.14,"dividendRate":0.014385,"openAndCloseTimeList":[[1780363800000,1780372800000],[1780376400000,1780387200000]],"volumeRatio":0.502667,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692","defaultTab":"news","newsList":[{"id":"1109494137","title":"翰森制药5月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1109494137","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109494137?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:49","pubTimestamp":1780390184,"startTime":"0","endTime":"0","summary":"翰森制药于2026年6月2日披露2026年5月股份变动月报表，显示公司截至2026年5月31日的注册股本与已发行股本均保持不变。根据公告，翰森制药目前的法定/注册股本数量为20,000,000,000股，面值为每股港币0.00001，总额约为20万元。本次月报表由联席公司秘书钟胜利女士签署，公司声明其已遵守香港联交所《上市规则》及相关法律法规的规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638166837","title":"港股异动 | 创新药概念股集体走低 加息预期压制行业估值及投融资环境 市场关注ASCO会议进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2638166837","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638166837?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:09","pubTimestamp":1779952150,"startTime":"0","endTime":"0","summary":"创新药、CXO 等成长赛道对流动性较为敏感，若美联储降息周期延后，或国内降准降息落地不及预期，市场流动性收紧将直接压制成长赛道估值。值得注意的是，2026年美国临床肿瘤学会年会将于5月29日至6月2日在美国芝加哥举行。本届ASCO共63项研究入选LBA，其中12家企业的13项研究来自中国，创历史新高；同时，94项中国研究入选口头汇报，数量近三年快速增长。上海证券指出，中国药企在国际平台彰显实力，中国创新药全球话语权逐年提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","LU0455707207.USD","BK1583","BK1521","LU2097828805.USD","BK1588","LU2328871848.SGD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","LU2488822045.USD","BK1589","00013","LU2097828714.EUR","VXUS","LU2097828557.USD","IE00BZ08YT58.USD","BK4588","LU2097828631.EUR","06978","BK1574","LU2242644610.SGD","BK1191","LU1969619763.USD","HK0000165453.HKD","01177","BK1161","BK4585","BK1587","159992","LU2097828474.EUR","01801","BK1515","LU0502904849.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160060542","title":"异动解读｜翰森制药盘中下跌6.04%，报31.76港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160060542","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160060542?lang=zh_cn&edition=full","pubTime":"2026-05-28 13:41","pubTimestamp":1779946909,"startTime":"0","endTime":"0","summary":"5月28日，翰森制药盘中下跌6.04%，报31.76港元/股，成交额1.71亿港元。翰森制药所在的制药行业中，板块整体承压，个股中，石药集团跌1.56%，中国生物制药跌3.4%，恒瑞医药跌2.24%，康哲药业跌4.15%，和黄医药跌4.71%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638585985","title":"中金：恒指季检调整后工业与医疗保健业覆盖度提升，6只股票或纳入港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2638585985","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638585985?lang=zh_cn&edition=full","pubTime":"2026-05-25 13:59","pubTimestamp":1779688785,"startTime":"0","endTime":"0","summary":"参照恒指公司的行业分类，此次恒指调整后，对于医疗保健业的覆盖度从38.8%提升至44.3%，对于工业的覆盖度从54.3%提升至56.0%。该行根据此次恒生综合指数调整情况、结合港股通纳入的额外要求，预计6只或符合港股通纳入范围。此次进入恒生综合指数的Minimax-W由于其同股不同权性质，需额外满足上市满6个月及20个交易日的条件，因此不会在本次6月调整中进入港股通，预计于8月纳入港股通。若后续满足市值与成交额要求，有望于8月纳入港股通。","market":"hk","thumbnail":"https://static.tigerbbs.com/38508134c6853c521e764dc952e7334a","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/38508134c6853c521e764dc952e7334a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7ab48a17674d5845193952fa54058c28","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445467.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03416","IE00B5MMRT66.SGD","LU0348783233.USD","LU1808992512.USD","09088","HSCEI","82800","00100","LU0348825331.USD","688235","LU1720050803.USD","09926","BK1191","513600","LU2399975544.HKD","03067","HSCI","09067","07300","HSTECH","IE00BPRC5H50.USD","03419","03115","LU0348766576.USD","03423","LU1770034418.SGD","02513","BK1151","LU1303224171.USD","LU0307460666.USD","LU1251922891.USD","BK1161","BK1568","BK1592","07288","03033","BK1175","BK1574","BK1583","LU2778985437.USD","BK1500","LU0348827113.USD","LU1794554557.SGD","82828","LU1961090484.USD","LU0634319403.HKD","BK1589","LU0417516738.SGD","LU0540923850.HKD","02837","LU2488822045.USD","LU0348767384.USD","03037","LU2476274720.SGD","02828","02833","LU0348784397.USD","601600","83115","IE00B543WZ88.USD","LU2328871848.SGD","BK1513","ONC","MCHmain","03417","03692","01519","09115","06160","LU0417516571.SGD","HK0000286598.CNH","LU1719994722.HKD","07588","03032","07552","LU0417516902.SGD","LU2476274308.USD","LU0348735423.USD","LU1969619763.USD","HSI","07200","LU0561508036.HKD","07500","HHImain","BK1117","03088","BK1588","LU0588546209.SGD","07226","02800","02600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637984387","title":"翰森制药(03692)：第四代EGFR-TKI HS-10504片用于非小细胞肺癌纳入突破性治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2637984387","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637984387?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:42","pubTimestamp":1779360179,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，于2026年5月21日，本集团自研第四代表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)HS-10504片获中国国家药品监督管理局(NMPA)批准纳入突破性治疗药物，拟定适应症为用于经EGFR-TKI治疗失败后伴EGFR C797S突变的局部晚期或转移性非小细胞肺癌(NSCLC)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药(03692)：第四代EGFR-TKI HS-10504片用于非小细胞肺癌纳入突破性治疗药物","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1583","03692","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635087677","title":"翰森制药(03692)：曾昭获委任为联席公司秘书、授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2635087677","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635087677?lang=zh_cn&edition=full","pubTime":"2026-05-15 21:03","pubTimestamp":1778850184,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，李亮贤先生由于个人工作安排已辞任公司联席公司秘书一职，并不再担任香港联合交易所有限公司证券上市规则第3.05条项下的公司授权代表，以及上市规则第19.05(2)条及公司条例(香港法例第622章)第16部项下所规定代表公司于香港接收法律程序文件及通知的公司授权代表(法律程序文件代理人)，自2026年5月15日起生效。曾昭女士已获委任为联席公司秘书、授权代表及法律程序文件代理人，自2026年5月15日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1583","BK1191","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635114782","title":"翰森制药(03692)：HS-10541片获国家药监局签发的药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2635114782","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635114782?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:34","pubTimestamp":1778675685,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，集团自主研发的1类新药HS-10541片获中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书，拟开展“用于KRAS G12C突变晚期实体瘤的治疗”的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","03692","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943788","title":"格隆汇个股放量排行榜 | 5月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943788","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635943788?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:30","pubTimestamp":1778664605,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日腾讯音乐-SW(01698)、阳光保险(06963)、上海电气(02727)、轻松健康(02661)、弘毅文化集团(00419)、FIT HON TENG(06088)、京城机电股份(00187)、北方矿业(00433)、心玮医疗-B(06609)、同源康医药-B(02410)、富通科技(00465)、京东物流(02618)、云顶新耀(01952)、赛晶科技(005","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/13173057083788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03888","00169","02096","01952","00772","01783","02197","09858","02285","06996","06963","02192","00136","06049","03700","01951","01548","02276","02172","01905","03692","06060","01357","00762","02158","06660","02171","06609","09992","09626","00719","01833","01024","00909","09699","02013","00013","02306","09688","06186","09888","01060","06160","06969","02126","02252","02618","01440","02256","81024"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634642240","title":"翰森制药(03692)：B7-H3靶向抗体-药物偶联物HS-20093用于食管鳞癌纳入突破性治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2634642240","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634642240?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:03","pubTimestamp":1778457784,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，于2026年5月9日，集团自研B7-H3靶向抗体-药物偶联物(ADC)注射用HS-20093获中国国家药品监督管理局(NMPA)批准纳入突破性治疗药物，拟定适应症为既往一线接受含铂化疗和免疫检查点抑制剂(ICI)治疗后失败的不可切除的局部晚期或转移性食管鳞癌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药(03692)：B7-H3靶向抗体-药物偶联物HS-20093用于食管鳞癌纳入突破性治疗药物","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","03692","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144457","title":"智通港股解盘 | AI热潮从硬件扩散到应用端 马斯克概念受到追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144457","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633144457?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:59","pubTimestamp":1778155199,"startTime":"0","endTime":"0","summary":"声明同时警告说，如果乌方在胜利日期间对莫斯科发动袭击，俄军将对基辅市中心实施大规模导弹打击，并呼吁平民及外国外交人员撤离基辅。希望俄乌双方保持克制，否则基辅陷入大的打击对市场会构成压力。这是自2022年11月以来连续第18个月增持黄金。当地时间周三，费城半导体指数刷新2000年3月9日以来最强五周滚动表现，该指数此期间累计涨幅超50%。中国高阶智驾仿真市场占有率达53.5%的头部企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BYV24P56.USD","CHAT","LU2097828474.EUR","03692","SG9999015952.SGD","AGIX","SG9999004220.SGD","IE00BZ08YT58.USD","BK1161","BK4588","DXYZ","01177","LU0502904849.HKD","01801","BK4585","00867","SG9999015945.SGD","SG9999015986.USD","LU0455707207.USD","LU2097828714.EUR","UFO","IE00BGHQDM52.EUR","LU2097828805.USD","03933","BK1583","IE00BVYPNQ40.USD","VXUS","HK0000165453.HKD","LU2488822045.USD","LU2328871848.SGD","IE00BVYPNP33.GBP","ARTY","BK1515","IE00BMCWC346.EUR","IE00BZ08YS42.EUR","LU2097828631.EUR","SG9999015978.USD","BK1589","BK1191","LU1969619763.USD","IE00BZ08YR35.GBP","BK1521","LU2097828557.USD","AIPO","BK1593","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193364706","title":"翰森制药2026年4月股份变动月报表：股本增至6,064,150,070股","url":"https://stock-news.laohu8.com/highlight/detail?id=1193364706","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193364706?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:47","pubTimestamp":1777884436,"startTime":"0","endTime":"0","summary":"翰森制药集团有限公司于2026年5月4日披露截至2026年4月30日的股份变动月报表，报告期内公司已发行及注册股本情况如下：。翰森制药在报告期末的法定注册股本为20,000,000,000股，每股面值为港币0.00001元，总注册股本为港币200,000元，与上月底相比没有变化。已发行股份方面，截至3月末，公司已发行股份数量为6,055,150,070股，报告期内新增发行9,000,000股，主要来自2019年5月27日批准及采纳的受限制股份单位计划。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631638874","title":"翰森制药(03692)：受托人根据受限制股份单位计划购入合共37万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2631638874","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631638874?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:33","pubTimestamp":1777545227,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，受限制股份单位受托人通知本公司，于2026年4月内，其已就受限制股份单位计划于市场上购入合共37万股股份(股份购入)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","BK1589","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631511169","title":"翰森制药(03692)：B7-H3靶向抗体-药物偶联物HS-20093用于去势抵抗性前列腺癌纳入突破性治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2631511169","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631511169?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:33","pubTimestamp":1777465983,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，于2026年4月29日，集团自研B7-H3靶向抗体-药物偶联物(ADC)注射用HS-20093获中国国家药品监督管理局(NMPA)批准纳入突破性治疗药物，拟定适应症为既往接受过新型内分泌治疗及紫杉类化疗的晚期去势抵抗性前列腺癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药(03692)：B7-H3靶向抗体-药物偶联物HS-20093用于去势抵抗性前列腺癌纳入突破性治疗药物","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","03692","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120022403","title":"翰森制药于2026年4月29日将Kiomedinevsone许可转让予江苏恒瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=1120022403","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120022403?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:21","pubTimestamp":1777465275,"startTime":"0","endTime":"0","summary":"翰森制药已于2026年4月29日，将其持有的Kiomedinevsone药物许可，正式转让给江苏恒瑞医药有限公司。此次许可转让标志着两家国内领先药企在创新药物资产优化配置方面的重要合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1191","03692","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630307337","title":"翰森制药(03692)授出合共代表499.23万股股份的受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2630307337","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630307337?lang=zh_cn&edition=full","pubTime":"2026-04-28 21:02","pubTimestamp":1777381340,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，于2026年4月28日，根据公司于2019年5月27日采纳之首次公开发售后受限制股份单位计划，向804名受限制股份单位承授人授出合共代表499.23万股股份的受限制股份单位，惟须经承授人接纳作实。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1583","03692","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172947342","title":"翰森制药将于2026年7月24日派发末期股息每股0.20港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172947342","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172947342?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:56","pubTimestamp":1777381014,"startTime":"0","endTime":"0","summary":"翰森制药(03692)4月28日发布公告，董事会宣布派发截至2025年12月31日止年度的末期股息，每股0.20港元，股东批准日期为2026年6月26日。该股息的除净日定于2026年7月3日，股东如欲符合收取股息分派资格，须于2026年7月6日16:30前递交股份过户文件。公司将于2026年7月7日至7月9日暂停办理股权登记，并以2026年7月9日作为记录日期，股息发放日为2026年7月24日。\n公告显示，公司执行董事包括主席兼执行董事钟慧娟女士、执行董事孙远女士及吕爱锋博士；独立非执行董事为林国强先生、陈尚伟先生、杨东涛女士及严嘉先生。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药将于2026年7月24日派发末期股息每股0.20港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629023400","title":"港股异动 | 创新药概念全线走低 油价上涨压制降息空间 市场关注创新药投融资前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2629023400","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629023400?lang=zh_cn&edition=full","pubTime":"2026-04-23 13:59","pubTimestamp":1776923941,"startTime":"0","endTime":"0","summary":"消息面上，地缘局势不确定性持续存在，油价上涨推升通胀预期压制降息空间。招商银行研究院发布报告称，2025年，受到全球地缘政治压力以及美联储降息节奏的影响，全球创新药融资同比下降7.1%，但Q3的融资额已恢复8%的正增长。2026年如果美伊战争影响逐渐消除，美联储仍能持续降息，创新药投融资有望持续恢复。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","OILK","LU1969619763.USD","PXJ","USOI","159992","LU2328871848.SGD","LU2097828557.USD","USE","DIG","LU2488822045.USD","OIH","BK1593","USL","LU2097828474.EUR","BWET","ERX","LU2242644610.SGD","LU0455707207.USD","BK4570","DUG","UGA","DRIP","BK1574","01530","BK1583","DBE","03692","IEO","VDE","HK0000165453.HKD","DBO","DBC","01801","OILU","BNO","LU0502904849.HKD","BK1191","GUSH","06978","LU2097828631.EUR","IXC","LU2097828714.EUR","DRLL","BK1589","VXUS","LU2097828805.USD","09995","OILT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629069622","title":"长春高新2025年净利润同比下降94%；翰森制药公布抗失眠新药临床数据｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2629069622","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629069622?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:02","pubTimestamp":1776812539,"startTime":"0","endTime":"0","summary":"｜2026年4月22日星期三｜NO.1长春高新2025年净利润1.55亿元，同比下降94%4月21日，长春高新披露2025年年度报告。2025年，公司实现营业收入120.83亿元，较上年同期降低10.27%；归属于上市公司股东的净利润为1.55亿元，较上年同期降低94%。公司拟向全体股东每10股派发现金红利1.60元(含税)，送红股0股，不以公积金转增股本。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223713055256.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713055256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","000661","159938","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629035089","title":"华源证券：维持翰森制药(03692)“买入”评级 创新管线逐步进入兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2629035089","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629035089?lang=zh_cn&edition=full","pubTime":"2026-04-21 15:58","pubTimestamp":1776758320,"startTime":"0","endTime":"0","summary":"翰森制药公布2025年报，总收入150.28亿元，同比增长22.6%，其中创新药与合作产品销售收入123.54亿元，同比增长30.4%，占总收入82.2%；溢利55.55亿元，同比增长27.1%。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260421/20260421155617_37933.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260421/20260421155617_37933.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["161027","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628719049","title":"招银国际：医疗板块风险偏好有温和的修复 推荐翰森制药(03692)等6股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628719049","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628719049?lang=zh_cn&edition=full","pubTime":"2026-04-20 11:36","pubTimestamp":1776656176,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，MSCI中国医疗指数2026年初至今累计上涨12.3%，跑赢MSCI中国指数13.6%。近期在中国政府工作报告将生物医学列为新兴支柱产业的政策催化下，板块风险偏好有温和的修复。同时，AI制药技术突破与中国创新药出海 BD 的爆发形成双重共振，该行预期产业基本面加速向好。招商国际给予该6只股份“买入”的投资评级，目标价分别为46.41港元、113.86港元、34.87港元、10.34港元、82港元及35.46美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","SG9999014674.SGD","LU2488822045.USD","LU0455707207.USD","BK1589","LU2097828805.USD","LU2097828474.EUR","03692","LU0502904849.HKD","LU2242644610.SGD","01167","LU2328871848.SGD","HK0000165453.HKD","LU2097828557.USD","02268","BK1191","BK1574","BK1583","LU2097828631.EUR","BK1161","LU1969619763.USD","01530","159891","LU2097828714.EUR","BK1141","01801"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0765},{"period":"1month","weight":-0.1606},{"period":"3month","weight":-0.0643},{"period":"6month","weight":-0.225},{"period":"1year","weight":0.2181},{"period":"ytd","weight":-0.1369}],"compareEarnings":[{"period":"1week","weight":-0.0081},{"period":"1month","weight":-0.0147},{"period":"3month","weight":-0.0144},{"period":"6month","weight":-0.0141},{"period":"1year","weight":0.0905},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品包括阿美乐、豪森昕福、迈灵达、孚来美、恒沐、昕越、圣罗莱等产品。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统（CNS）疾病、代谢及其他治疗领域。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.002565},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.01282},{"month":3,"riseRate":0.428571,"avgChangeRate":0.023369},{"month":4,"riseRate":0.571429,"avgChangeRate":0.03396},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.00521},{"month":6,"riseRate":0.571429,"avgChangeRate":0.046313},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.000332},{"month":8,"riseRate":0.714286,"avgChangeRate":0.01897},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.033021},{"month":10,"riseRate":0.142857,"avgChangeRate":0.001586},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063467},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016858}],"exchange":"SEHK","name":"翰森制药","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰森制药,03692,翰森制药股票,翰森制药股票老虎,翰森制药股票老虎国际,翰森制药行情,翰森制药股票行情,翰森制药股价,翰森制药股市,翰森制药股票价格,翰森制药股票交易,翰森制药股票购买,翰森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}